[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"basal-cell-carcinoma-of-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:basal-cell-carcinoma-of-skin":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,72,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100640027","phase-1-a-first-in-human-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-kup-101a-in-patients-with-selected-advanced-solid-tumors-100640027",false,"NCT07600476","A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available\n* ECOG Performance status of 0 to 2\n* Adequate hematological, renal, and hepatic organ function\n\nExclusion Criteria:\n\n* Previous systemic treatment with TLR agonists, with the exception of TLR agonists used as vaccine adjuvants.\n* Known additional malignancy that is progressing or requires active treatment\n* Diagnosis of immunodeficiency\n* Active autoimmune disease not caused by prior anticancer treatment that required systemic immunosuppressive treatment in the past 2 years\n* Active autoimmune disease caused by prior anticancer treatment, unless currently controlled by replacement therapy only.\n* Any kind of leukemia\n* Previously received an organ transplant (other than corneal transplants) or hematopoietic stem cell transplantation\n* Known active central nervous system metastases and\u002For carcinomatous meningitis\n* Cerebral vascular event within 6 months before Screening\n* Unstable cardiopulmonary status defined by uncontrolled congestive heart failure of New York Heart Association Grade III or IV, unstable angina, or myocardial infarction within 6 months before Screening\n* High grade ocular disease such as uncontrolled glaucoma","ALL","18 Years",{"count":18,"type":19},21,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.",[25,26,27,28,29],"Cutaneous Melanoma","Mucosal Melanoma","Cutaneous Squamous Cell Carcinoma (CSCC)","Merkel Cell Carcinoma of Skin","Basal Cell Carcinoma of Skin",[31,32,33,34,35,36],"TLR4 agonist","TLR7 agonist","TLR4\u002F7 agonist","skin cancer","innate immunity","immunotherapy","RECRUITING","2026-05-13",{"date":40,"type":41},"2026-05-20","ACTUAL",{"date":43,"type":19},"2026-04",{"date":45,"type":19},"2028-12",{"name":47,"class":48},"Kupando GmbH","INDUSTRY",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":4},"100620516","ai-enhanced-oct-imaging-for-pre-surgical-margin-detection-of-basal-cell-carcinoma-100620516","NCT07358637","AI-enhanced OCT Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma","Artificial Intelligence Enhanced Optical Coherence Tomography (AI-OCT) Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma","Inclusion Criteria:\n\n* Male or Female, ages 18 or older\n* at least one biopsy proven superficial or nodular BCC\n* willingness to have photographs taken of the treatment area\n* ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* infiltrative, micronodular, or morpheaform BCC\n* pregnant women\n* subjects not willing to have a biopsy taken from the treatment area\n* subjects with herpes simplex virus infection in the treatment area",{"count":58,"type":19},30,"OBSERVATIONAL","Basal cell carcinomas (BCCs) are the most common human malignancy, affecting about 2 million Americans each year. Mohs micrographic surgery (MMS) removes tissue by sequential excision. Costs for MMS could be reduced if the number of necessary excision stages were decreased by a more accurate initial tumor margin assessment.\n\nThe goal of this observational study is to learn if Optical Coherence Tomography (OCT) used in conjunction with artificial intelligence algorithms is accurate in the detection of superficial BCC margins prior to MMS. This study also aims to determine if AI-OCT guided margin delineation can reduce the number of stages in MMS.\n\nResearchers will first focus on validating AI-OCT as a method for accurately detecting BCCs. A follow-up study would then address the guided pre-surgical margin delineation.",[29],"NOT_YET_RECRUITING","2026-04-30",{"date":65,"type":41},"2026-05-06",{"date":67,"type":19},"2026-09",{"date":45,"type":19},{"name":70,"class":71},"Henry Ford Health System","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":82,"conditions":83,"keywords":90,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100631522","real-world-evaluation-of-the-implementation-of-lc-oct-in-daily-clinical-practice-100631522","NCT07501780","Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice","Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice: a Retrospective Observational Study","RELI","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* LC-OCT performed as part of diagnostic evaluation between January 2025 and June 2025 at Mohs clinics in the Netherlands\n* Histopathological results (biopsy or excision) and\u002For 6-12 month clinical follow-up data available\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Cases without histopathological confirmation or available follow-up data",{"count":81,"type":19},297,"Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions.\n\nThis retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.",[29,84,85,86,87,88,89],"Optical Coherence Tomography (OCT)","Neoplasms","Neoplasms, Basal Cell","Carcinoma, Basal Cell (BCC)","Real-world Study","Implementation",[91,92,93],"Line-Field Optical Coherence Tomography","Real-world evaluation","Non-melanoma skin cancer","2026-03-24",{"date":96,"type":41},"2026-03-30",{"date":98,"type":19},"2026-03-15",{"date":100,"type":19},"2027-12-01",{"name":102,"class":71},"Maastricht University Medical Center",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":114,"conditions":115,"keywords":121,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":103},"100620749","impact-of-preoperative-high-frequency-ultrasound-cutaneous-lesion-extent-assessment-on-excision-margin-positivity-in-head-and-neck-skin-cancer-and-the-relationship-between-preoperative-assessment-methods-inadequate-excision-margins-and-tumor-recurrence-100620749","NCT07361666","Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence","Impact of Preoperative High-Frequency Ultrasound Cutaneous Lesion Extent Assessment on Excision Margin Positivity in Head and Neck Skin Cancer, and the Relationship Between Preoperative Assessment Methods, Inadequate Excision Margins, and Tumor Recurrence (HFUS-CLEAR)","HFUS-CLEAR","Inclusion Criteria:\n\n* Cutaneous lesion located in the head and neck region with a preoperative diagnosis of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), established by dermoscopy or biopsy, and qualified for surgical excision with curative intent.\n* patient age of 18 years or older.\n* Ability of patient to provide voluntary, informed, written consent for participation in the study.\n* Confirmation that the patient has read and understood the Patient Information Sheet.\n\nExclusion Criteria:\n\n* Excisional biopsies without radical intent.\n* Lack of histopathologic confirmation of BCC or SCC in the postoperative specimen (incorrect dermoscopic qualification).\n* Inability to perform radical surgical excision due to excessive tumor extent, poor general condition of the patient, or lack of patient consent for surgery.\n* Pregnancy.",{"count":113,"type":19},400,"Non-melanoma skin cancers (NMSC), particularly basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), are the most common malignancies in Caucasians, with the majority of tumors located in the head and neck due to chronic ultraviolet exposure. Although BCC has very low metastatic potential, while cSCC carries a higher risk of nodal spread, both can cause significant local tissue destruction and functional and cosmetic impairment. Complete excision with histologically clear margins remains the standard treatment; however, incomplete or close excision margins are reported in a substantial proportion of cases and are associated with increased risk of local recurrence, need for additional treatment, and higher healthcare costs.\n\nPreoperative dermoscopy improves delineation of lateral tumor borders but does not assess depth of invasion. High-frequency ultrasound (HFUS) is a rapid, non-invasive imaging modality that can visualize superficial skin structures and estimate tumor thickness. Previous studies have suggested good agreement between HFUS and histopathologic depth of invasion, but results are not fully consistent, and HFUS has not yet been incorporated into major guideline recommendations for preoperative assessment of NMSC. Further prospective data are needed to clarify whether HFUS can improve surgical planning and margin control.\n\nThis prospective study is designed to assess the impact of adding preoperative HFUS to standard dermoscopic evaluation in head and neck BCC and cSCC. The primary objectives are: (1) to compare the frequency of positive or inadequate (\\\u003C1 mm) histopathologic excision margins between lesions assessed with dermoscopy alone and those assessed with both dermoscopy and HFUS; and (2) to evaluate 5-year local recurrence rates in relation to preoperative assessment method, histopathologic margin status, and subsequent management of inadequate margins (observation, non-surgical treatment, or scar excision). Secondary and additional objectives include: assessing concordance between HFUS-measured and histopathologic depth of invasion; determining the frequency of residual tumor in scars excised after inadequate margins; evaluating recurrence rate according to the site of inadequate margins (lateral vs deep); and identifying patient-related, tumor-related, surgical, and histopathologic predictors of inadequate margins and recurrence. Approximately 400 lesions (BCC or cSCC of the head and neck) qualified for curative surgical excision will be included. Each lesion will constitute an independent study case. All lesions will undergo preoperative assessment, including clinical evaluation with detailed medical history and dermoscopy; in one cohort, lesions will additionally be evaluated with HFUS. HFUS will be performed with an 18-MHz linear probe, using superficial B-mode and color Doppler. Maximum tumor depth will be recorded from the epidermal surface (or granular layer) to the deepest hypoechoic point, with assessment of potential infiltration of deeper structures when visible. Surgical excision and postoperative care will follow standard clinical practice. Postoperative histopathologic assessment of FFPE tumor samples will record tumor histologic type and subtype, margin status, width, depth of invasion, differentiation, inflammation, elastosis, perineural or vascular invasion, and other routinely assessed diagnostic features. In the event of positive or inadequate excision margins, patients will be referred, after consultation with a dermatologist, for further management (observation, non-surgical treatment, or scar excision), depending on clinical indications and patient preferences. Participation in the study will not influence the primary surgical treatment or any decisions regarding subsequent management.\n\nPatients will be followed for at least 5 years according to current clinical guidelines, with dermoscopic skin examination and documentation of local recurrence and its management. The study aims to determine whether incorporating HFUS into preoperative assessment can reduce the frequency of inadequate histologic margins and improve long-term local control in head and neck NMSC.",[29,27,116,117,118,119,120],"Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)","Cutaneous Squamous Cell Carcinoma of the Head and Neck","Basal Cell Carcinoma (BCC)","Basal Cell Carcinoma of the Head and Neck","Non-Melanoma Skin Cancer (NMSC)",[122,123,124,125,126,127,128,129,130],"Basal Cell Carcinoma","Squamous Cell Carcinoma","Skin Cancer","Skin Neoplasms","Margins of Excision","Positive Surgical Margins","Recurrence","high-frequency ultrasound","HFUS","2026-01-15",{"date":133,"type":41},"2026-01-23",{"date":135,"type":19},"2025-12-23",{"date":137,"type":19},"2033-11-30",{"name":139,"class":140},"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","OTHER_GOV"]